Elisabet Salsench
Overview
Explore the profile of Elisabet Salsench including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vila-Corcoles A, Ochoa-Gondar O, Hospital I, de Diego C, Satue E, Blade J, et al.
Hum Vaccin Immunother
. 2016 Jul;
12(11):2953-2958.
PMID: 27454779
There is scarce data about pneumococcal vaccination coverages among adults in recent years. We investigated current pneumococcal vaccination coverages in Catalonia, Spain, with a cross-sectional population-based study including 2,033,465 individuals...
2.
Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A, Gomez F, et al.
BMC Public Health
. 2012 Mar;
12:222.
PMID: 22436146
Background: Conflicting results have been recently reported evaluating the relationship between pneumococcal vaccination and the risk of thrombotic vascular events. This study assessed the clinical effectiveness of the 23-valent polysaccharide...
3.
Vila-Corcoles A, Ochoa-Gondar O, Guzman J, Rodriguez-Blanco T, Salsench E, Fuentes C
BMC Infect Dis
. 2010 Mar;
10:73.
PMID: 20298596
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently recommended in elderly and high-risk adults. However, its efficacy in preventing pneumococcal infections remains controversial. This study assessed the clinical effectiveness...
4.
Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, de Diego C, Salsench E, Raga X, et al.
BMC Public Health
. 2010 Jan;
10:25.
PMID: 20085658
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events...
5.
Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, et al.
Vaccine
. 2009 Jan;
27(10):1504-10.
PMID: 19171174
The 23-valent polysaccharide pneumococcal vaccine is currently recommended in elderly and high-risk adults. Its efficacy against invasive pneumococcal disease has been demonstrated, but its effectiveness in preventing pneumonia remains uncertain....
6.
Vila-Corcoles A, Rodriguez T, de Diego C, Ochoa O, Valdivieso A, Salsench E, et al.
Vaccine
. 2007 Aug;
25(37-38):6699-707.
PMID: 17698263
This study assessed the relationship between the reception of conventional inactivated influenza vaccine and winter mortality in a prospective cohort that included 11,240 Spanish community-dwelling elderly individuals followed from January...